Glioblastoma
Drug research and approvals for glioblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 320 studies of glioblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 48 drug trials for it since 2013, FDA has 3 approved and 79 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 320
- Trials authorized in Canada: 48
- FDA orphan approvals: 3
- EU medicines: 5
Recruiting Now
Newest start dates first, of 320 recruiting on ClinicalTrials.gov ↗- Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed GlioblastomaNCT07884344 · Early Phase 1 · Macarena De La Fuente, MD · starts Dec 1, 2026
- TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly GliomaNCT07862647 · Phase 1 · Alpheus Medical, Inc. · starts Oct 29, 2026
- A Phase I Clinical Study of YN003 in the Treatment of GliomaNCT07929909 · Phase 1 · Beijing Inno Medicine Co., Ltd. · starts Oct 27, 2026
- Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma PatientsNCT07775534 · Not applicable · City of Hope Medical Center · starts Oct 23, 2026
- Pharmacoscopy for Patients With Refractory Primary Brain TumorsNCT06804655 · Phase 2 · University of Zurich · starts Sep 11, 2026
- VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent GliomaNCT07831369 · Phase 2 · Inova Health Care Services · starts Sep 4, 2026
- Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype GlioblastomaNCT07708961 · Phase 2 · Mayo Clinic · starts Aug 28, 2026
- REMIND Maintenance Radiotherapy for Newly Diagnosed GlioblastomaNCT07831772 · Not applicable · University of Minnesota · starts Aug 24, 2026
- A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric…NCT07579208 · Phase 1 · M.D. Anderson Cancer Center · starts Aug 21, 2026
- Irinotecan-ChemoSeed in Surgically Resectable GlioblastomaNCT07356973 · Phase 2 · CRISM Therapeutics LTD · starts Aug 20, 2026
Trials Authorized in Canada
The 10 newest of 48; search them all in Canada trials| Oct 16, 2026 | Novel endovascular therapy with bevacizumab and cannabinoids for glioblastomaAVASTIN / SATIVEX / OSMITROL INJECTION 20% | ST MICHAELS HOSPITAL | Pending |
| Oct 1, 2026 | A phase 1 safety and feasibility trial of focused ultrasound for the treatment of high-grade glioma in patients undergoing standard chemotherapy (gb7260)PERFLUTREN (PERFLUOROPROPANE) | SUNNYBROOK RESEARCH INSTITUTE | Pending |
| Mar 20, 2025 | A phase 1/2 study to assess bdtx-1535, an oral egfr inhibitor, in patients with glioblastoma or non-small cell lung cancerSILEVERTINIB (BDTX-1535) | BLACK DIAMOND THERAPEUTICS, INC. | Ongoing |
| Nov 15, 2024 | A phase 3, randomized, double-blind, placebo-controlled study of optune® (ttfields, 200 khz) concomitant with maintenance temozolomide and pembrolizumab versus…PEMBROLIZUMAB | NOVOCURE GMBH | Ongoing |
| Oct 16, 2024 | A phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with…NIRAPARIB | NEUROTRIALS LLC | Ongoing |
| Jan 12, 2024 | Fet-pet/mri based treatment planning for glioblastoma multiforme in post-surgical patientsO-(2-[18F]-FLUOROETHYL)-L-TYROSINE ([18F] FET) | SUNNYBROOK RESEARCH INSTITUTE | Pending |
| Aug 1, 2023 | A randomized phase II study on intra-arterial carboplatin combined with caelyx compared to intra-arterial carboplatin combined with etoposide phosphate for…DOXORUBICIN / CARBOPLATIN / ETOPOSIDE PHOSPHATE | CIUSSS DE L'ESTRIE - CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE | Ongoing |
| Apr 20, 2023 | Study of opdualag (novolumab and relatlimab) in relapsed hypermutant glioblastoma: a pediatric oncology precision medicine studyOPDUALAG | C17 COUNCIL | Closed |
| Dec 1, 2022 | A phase III trial of lomustine-temozolomide combination therapy versus standard temozolomide in patients with methylated mgmt promoter glioblastomaLOMUSTINE | NRG ONCOLOGY | Closed |
| Jun 23, 2022 | A pivotal study to evaluate the safety and effectiveness of exablate model 4000 using microbubble resonators to temporarily mediate blood-brain barrier…PERFLUTREN | Insightec | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 82| May 5, 2009 | AvastinTreatment of glioblastoma with progressive disease following prior therapy | Genentech, Inc. | Approved |
| Mar 15, 2005 | TemodarTreatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment | Schering-Plough Research Institute | Approved |
| Sep 23, 1996 | GliadelAs an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated | Guilford Pharmaceuticals, Inc. | Approved |
| Oct 16, 2025 | tinostamustinetreatment of glioblastoma | Knoa Pharma LLC | Designated |
| Jul 11, 2025 | cintredekin besudotox (CB)treatment of malignant glioma (glioblastoma multiforme) | Precision Neuromed | Designated |
| Feb 13, 2025 | FGFR3 targeting antibody-drug conjugatetreatment of glioblastoma, glioma (harboring the FGFR3-TACC3 fusion) | Biohaven Therapeutics Ltd. | Designated |
| Nov 18, 2024 | honokioltreatment of glioblastoma multiforme (GBM) | Chengdu Jinrui Foundation Biotechnology Co., Ltd. | Designated |
| Sep 10, 2024 | temozolomidetreatment of glioblastoma multiforme in pediatric patients | Accord Healthcare Inc | Designated |
| Jul 25, 2023 | Maytansine bound via linker to bacterial derived,…Treatment of Glioblastoma Multiforme | CyGenica Ltd. | Designated |
| Jun 21, 2023 | (7S)-N-(3-bromo-2-fluorophenyl)-7-[(4-methylpiperazin-1-yl)m…Treatment of glioblastoma | Katmai Pharmaceuticals | Designated |
| Mar 1, 2023 | Autologous CD34+ cell enriched haematopoietic stem and…Treatment of glioblastoma multiforme | Genenta Sciences | Designated |
| Feb 27, 2023 | Gallium maltolateTreatment of glioblastoma | Imaging Biometrics, LLC | Designated |
| Feb 14, 2023 | (-)-B-ElemeneTreatment of Glioblastoma Multiforme | Sichuan Honghe Biotechnology Co., Ltd. | Designated |
| Jan 25, 2023 | Degrader of Lysine-specific histone demethylase 1A and REST…Treatment of Glioblastoma | Beactica Therapeutics AB | Designated |
| Jan 18, 2023 | (S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-…Treatment of Glioblastoma (GBM) | Jubilant Therapeutics Inc. | Designated |
Medicines Authorised in the EU
Newest first| Jul 13, 2011 | Temozolomide Suntemozolomide · generic | Sun Pharmaceutical Industries Europe B.V. | EMA ↗ |
| Mar 15, 2010 | Temozolomide Accordtemozolomide · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jan 28, 2010 | Temozolomide Tevatemozolomide · generic | Teva B.V. | EMA ↗ |
| Jan 25, 2010 | Temomedactemozolomide · generic | medac Gesellschaft für klinische Spezialpräparate mbH | EMA ↗ |
| Jan 26, 1999 | Temodaltemozolomide | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA